key: cord-1030863-ikbtcift
authors: Mohamed Kamel, Gellan Alaa; Harahsheh, Eman; Hussein, Shaimaa
title: Diacerein ameliorates acetaminophen hepatotoxicity in rats via inhibiting HMGB1/TLR4/NF-κB and upregulating PPAR-γ signal
date: 2022-04-02
journal: Mol Biol Rep
DOI: 10.1007/s11033-022-07366-5
sha: 039b263f6633e2d1a2548351d23d1e6428b43986
doc_id: 1030863
cord_uid: ikbtcift

BACKGROUND: Acetaminophen (APAP) is a worldwide antipyretic as well as an analgesic medication. It has been extensively utilized during the outbreak of coronavirus 2019 (COVID-19). APAP misuse would lead to liver injury. Diacerein (DIA), an anthraquinone derivative, has antioxidant and inflammatory properties. Hence, this study attempted to evaluate the impact of DIA treatment on liver injury induced by APAP and its influence on nuclear factor-κB (NF-κB) /toll-like receptor 4 (TLR4)/high mobility group box-1(HMGB-1) signaling as well as the expression of peroxisome proliferator-activated receptor-gamma (PPAR-γ) expression. METHODS: Male albino rats received 25 as well as 50 mg/kg/day DIA orally for seven days. One hour after the last administration, rats received APAP (1gm/kg, orally). For histopathological analysis, liver tissues and blood were collected, immunohistochemical (IHC) assay, biochemical assay, as well as quantitative real-time polymerase chain reaction (qRT-PCR). RESULTS: DIA markedly reduced liver injury markers and ameliorated histopathological changes. Moreover, DIA dose-dependently alleviated oxidative stress status caused by APAP administration along with inflammatory markers, including the level of interleukin-1 beta (IL-1β), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), and interleukin 6 (IL-6). Furthermore, DIA downregulated protein levels as well as mRNA of HMGB-1, TLR4, NF-κB p65 expression, and enhanced PPAR-γ expression. Moreover, DIA ameliorated apoptotic (Bax) and caspase-3 expressions and increased the anti-apoptotic (Bcl2) expression. CONCLUSIONS: This study demonstrated that DIA exerts anti-apoptotic, anti-inflammatory, and antioxidant properties against liver injury induced by APAP that is attributed to inhibition of the HMGB1/TLR4/NF-κB pathway, besides upregulation of the expression of PPAR-γ.

Acetaminophen (APAP) is widely utilized as an overthe-counter drug for treating inflammation, fever, as well as pain [1] . APAP is currently the main antipyretic and analgesic drug recommended by several studies over nonsteroidal anti-inflammatory drugs (NSAIDs) used to manage fever and pain associated with the pandemic infection of coronavirus 2019 . This assumption could cause a possible misuse of acetaminophen, which is considered the major cause behind drug-induced liver injury (DILI) worldwide. [1] [2] [3] . Although N-acetylcysteine (NAC) is the current drug used to protect against liver injury induced by APAP, it is only effective when given an early period of APAP ingestion and associated with adverse effects such as nausea, vomiting, allergic reactions, and headaches [4] . It is pivotal to find new therapeutic targets and effective agents.

Inflammation and elevated oxidative stress significantly contribute to APAP hepatotoxicity, resulting in hepatocyte necrosis and apoptosis [3, 5] . Consequently, necrotic hepatocytes induce damage-associated molecular patterns (DAMPs like high mobility group box 1(HMGB1 that is determined by toll-like receptor 4 (TLR, and activate the innate immune system and release excessive inflammatory mediators, including cytokines including nuclear factor-κB (NF-κB), tumor necrosis factor-alpha (TNF-α), as well as interleukin 1 beta (IL-1β), which eventually leads to severe hepatic injury [4, 6, 7] . Peroxisome proliferatoractivated receptor-γ (PPAR-γ), which belongs to the family of the nuclear hormone receptors, was proven to enhance the antioxidant and anti-inflammatory gene transcription [8] , modulate TLR4 activation [9] , and regulate NF-κBinduced inflammation [10] .

Diacerein (DIA), anthraquinone derivatives, is an antiinflammatory, analgesic, and antipyretic drug used clinically to treat osteoarthritis. Furthermore, rhein, the active metabolite of DIA, was demonstrated to induce several pharmacological activities, such as anti-inflammatory, antioxidant, and antitumor [11] . DIA is an IL-1β inhibitor which evidenced to markedly protected against inflammatory damage via its ability to inhibit inflammatory cytokines like IL-1β and TNF-α [12] , in addition to downregulating the TLR4/NF-κB-mediated signaling pathway activation, followed by suppressing the secretion of inflammatory cytokines [13] . It has been proven that DIA has a hepatoprotective impact against liver ischemia and reperfusion (I/R) via its antioxidant and anti-inflammatory activities [13] . However, its effect on liver injury induced by APAP remains unclear. Hence, this study attempted to examine the potential protective impact of DIA on hepatotoxicity induced by APAP and explore its impact on HMGB-1/TLR4/NF-κB, Bax/Bcl2/caspase-3 signaling pathway, and PPAR-γ expression.

The chemicals utilized were highly analytical and purchased from Sigma-Aldrich (St. Louis, MO, USA). Paracetamol (Paramol ®) tablets (500 mg) were obtained from Misr Co. for Pharmaceutical Industries (Cairo, Egypt). They were dissolved in saline. DIA powder was purchased from Eva Pharma Company (Cairo, Egypt) and dissolved in 1% carboxymethyl cellulose (CMC).

Twenty-four male albino rats, with nearly 150 to 180 g, were purchased from the animal facility of The Nile Co. for Pharmaceuticals and Chemical Industries (Cairo, Egypt). Animals were kept in a controlled environment at a temperature between 20 to 25 °C, 55% humidity, as well as a 12-h light/dark cycle. They were supplied with free drinking and given a regular diet. One week prior to the experiment, animals were acclimatized. The experiment was carried out based on The Public Health Guide for the care and use of laboratory animals, as well as the Faculty of Pharmacy's Animal Ethics Committee, Al-Azhar University, Egypt.

The animals were randomized into four groups (n = 6 rats per group).

Control group; animals were administrated 1% CMC and saline for seven days. APAP group; rats were given a single APPA dose (1 g/kg, orally) [14] on the seventh day of the trial. DIA 25 + APPA and DIA 50 + APPA groups; rats received diacerein (25 and 50 mg/kg, orally) [15] respectively for a week, and subsequently were given APPA (1 g/kg, orally) on the last day of the experiment. Twenty-four hours after APAP exposure, in order to evaluate aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), total bilirubin (TBB), lactate dehydrogenase (LDH), and blood samples were obtained. Afterward, rats were sacrificed, livers were dissected, washed in ice-cooled saline, and dried. Each dissected liver was subdivided into three sections: the first was preserved in a formalin solution of 10% for immunohistochemical and histopathological analysis. With regard to the second section, it was promptly frozen in liquid nitrogen and kept at − 80 °C for the analysis of gene expression. Finally, the third section was homogenized in saline for subsequent biochemical analysis.

Serum of rats used for assay of ALT, AST, and TBB using colorimetric kits (Abcam, UK), while LDH assayed using Randox (UK) kit following the instructions of the manufacturer.

The samples from the liver were preserved in a formalin of 10%, fixed in paraffin, dissected into 5-μm thickness sections, and stained with eosin and hematoxylin [16] .

The determination of lipid peroxidation in hepatic tissue homogenate was performed by measuring malondialdehyde (MDA) content using a commercial kit (Bio-diagnostic Co., Egypt). Diminished glutathione (GSH) level as well as glutathione peroxidase activity (GPx), superoxide dismutase (SOD), and catalase (CAT) activities were performed utilizing kits purchased from (Bio-diagnostic Co., Egypt). It should be noted that the procedures were carried out, and parameters were determined following the protocol of the manufacturer.

Enzyme-linked immunosorbent assay (ELISA) for hepatic HMGB1, TLR4, IL-1β, IL-6, TNF-α, and MPO levels TLR4 and HMGB1 protein levels were determined using an ELISA kit (My BioSource, USA). IL-6, IL-1β, TNF-α, and MPO were quantified in hepatic tissue homogenate utilizing ELISA kits purchased from (RandD Systems, Inc, USA), (San Diego, California, USA), (Cloud-clone corp., USA), and (My BioSource, USA) respectively. Measurement of sample concentration as well as the measurement of all parameters was performed in accordance with the protocol of the manufacturer.

Paraffined blocks of hepatic tissue were sectioned and deparaffinized with xylene and subsequently rehydrated with alleviated concentrations of alcohol. The sections were left for 10 min in 3% H 2 O 2 followed by 30 min in 0.1% trypsin at 37 °C, for antigen retrieval. They were subsequently incubated overnight at 4 °C with antibodies of polyclonal rabbit against Bcl2, NF-κB (p65), Bax, PPAR-γ, and caspase-3 (1:1000 dilution; Abcam, Cambridge, UK). Sections were treated at 37 °C for 30 min with biotinylated goat anti-rabbit (Invitrogen), the secondary antibody, and subsequently stained with 3, 3-diaminobenzidine and eventually counterstained with hematoxylin. Afterward, image analysis was carried out via ImageJ software (version 1.48) to assess the area percent (A%).

Following the instructions of the manufacturer, the isolation of total RNA from the liver was performed utilizing a commercial kit (QIAzole and Qiagen RNeasy Mini Kits). The purity and the concentration of the isolated RNA were evaluated using the Nanodrop (ND-1000 USA). The primers used for assessment were obtained from (Invitrogen Life Technologies, Carlsbad, CA, USA). The primers' sequences utilized are like the following: HMGB-1 forward AGG CTG ACA AGG CTC GTT ATG; reverse TGT CAT CCG CAG CAG TGT TG, TLR4 forward GGG GGG TAT TTG ACA CAC TCTA; reverse TCC TTT GGA TGT CTC TAT GCGA, β-actin forward GGA GAT TAC TGC CCT GGC TCC TAG C; reverse GGC CGG ACT CAT CGT ACT CCT GCT T.

qRT-PCR was car ried out utilizing Quanti-Tect® SYBR® Green RT-PCR master mix Kit (Qiagen, Hilden, Germany). Following a 10-min hot start at 95 °C, samples at 95 °C were exposed to 15 s of denaturation followed by 1 min of annealing for 45 cycles at 54-58 °C. Melting curve analysis was done from 60 °C to 95 °C, with temperature increments of 0.5 °C every 10 s to detect any nonspecific products. The Ct value was calculated using the thermal cycler's (Veriti®) software package, in which the ΔCt value denoted the number of the cycle when the fluorescence curve passed the baseline score. Based on the 2 −ΔΔCt method, the target genes' relative expression of mRNA was determined via normalizing the control group and the housekeeping gene -actin.

Statistical analysis of the experimental results was performed utilizing the GraphPad Prism (version 5.0, GraphPad Software Inc., San Diego, California) and expressed in the form of mean ± S.E.M. The one-way ANOVA was utilized to analyze data, whereas Tukey's post hoc tests were utilized for making comparisons. P < 0.05 was deemed significant.

As depicted in Table 1 , administration of APAP significantly elevated ALT, AST, TBB, and LDH serum levels by 151%, 111.4%, 224%, and 132%, respectively, than controls.

However, DIA (25 and 50 mg/kg) pre-treatment resulted in a substantial decline in AST, ALT, TBB, and LDH serum levels by (40%, 40.5%, 47%, and 37.5%) and (53%, 71%, 57%, and 42%), respectively, in a dose-related manner than the group treated with APAP. These results demonstrated that DIA induces a protective impact against liver damage induced by APAP.

According to microscopic examination in Fig. 1 , the histology of control rats' H&E-stained liver sections was normal (Fig. 1A) . The dissected liver sections from the rats treated with APAP demonstrated diffuse hepatocellular vacuolation and congestion. In addition, the portal areas contained mononuclear inflammatory cells infiltration (Fig. 1B) . Furthermore, portal fibroplasia was noticed along with the detected inflammatory reaction (Fig. 1C) and necrosis (Fig. 1D) . However, pretreatment with DIA (25 and 50 mg/ kg) ameliorated APAP-induced histopathological changes ( Fig. 1E-H) . 

As depicted in Fig. 2A , B, C, D, administration of APAP markedly increased TNF-α, IL-1β, and IL-6 hepatic levels by 128%, 181%, and 143%, respectively than controls. In contrast, pretreatment with DIA (25 and 50 mg/kg) markedly reduced these changes by ([33%, 30%, and 29%) and (47%, 50%, and 45%] respectively) in a dose-depended manner than animals treated with APAP. These findings revealed that DIA could alleviate the inflammation induced by APAP. In Fig. 2D , neutrophil infiltration was assessed via the evaluation of MPO. Hepatic MPO level was increased in APAP-treated rats by 188% than controls. In comparison to rats treated with APAP, DIA pretreatment (25 and 50 mg/kg) reduced the increased MPO level by 39% and 52%, respectively. These findings verified that DIA could improve neutrophil infiltration in APAP-induced liver injury in a dosedependent manner.

As demonstrated in Fig. 3A and B, administration of APAP substantially increased the mRNA expression of TLR4 HMGB1 by 2.7 and 1.7-fold, respectively, in comparison to controls. Consequently, APAP elevated HMGB1 and TLR4 protein levels by 117.5% and 214%, respectively, compared to control rats ( Fig. 3C and D) . DIA pretreatment (25 and 50 mg/kg) considerably downregulated the mRNA expression of TLR4 and HMGB1 by ([25% and 26%] and [43% and 39%], respectively) as well as decreased the protein levels of both by ([22% and 33%] and [34% and 48%] respectively), compared to the APAP-treated rats.

In Fig. 4 , the IHC examination of NF-κB (p65) expression displayed a strong positive reaction in the APAP-treated rats compared to the control group (Fig. 4B) . Pretreatment with DIA (25 and 50 mg/kg) substantially decreased NF-κB (p65) expression in a dose-depended manner ( Fig. 4C and D) compared to APAP-treated rats.

As depicted in Fig. 5 , immunostaining of PPAR-γ expression displayed weak expression in APAP-treated rats' liver tissues than controls (Fig. 5B) . In contrast, pretreatment with DIA (25 and 50 mg/kg) displayed a strong positive reaction in a dose-depended manner in comparison to animals treated with rat APAP (Fig. 5C and D) .

As displayed in Fig. 6A , B, C, D, and E, the IHC examination of Bax, active caspase-3, and Bcl2 in the liver tissue sections demonstrated an elevated expression of both Bax 

Hepatoxicity triggered by an acute overdose of APAP is considered the main cause of DILI [2] . Several researchers illustrated that DIA has anti-inflammatory and antioxidant properties [12, 14, 15] . Studies have shown that DIA protects testicular injury, nephrotoxicity, and hepatotoxicity [13] . Hence, the present study investigated the hepatoprotective DIA impact against liver injury induced by APAP, denoting modulation of TLR4/ HMGB-1 as well as PPAR-γ signaling pathways. Rats that received acute APAP overdose exhibited marked hepatocellular injury in rats verified by the significant increase in the liver index as well as serum levels of AST, ALT, TBB, and LDH. These enzymes are reliable indicators for liver injury, and assessing their serum levels helps identify hepatocellular damage. The histopathological analysis further confirmed the APAP-induced liver injury [14] . Pretreatment with DIA (25 and 50 mg/kg) markedly and dose-dependently protect against APAP-induced liver injury through a reduction in liver function markers, together with alleviating histopathological changes of hepatic tissue, which is in agreement with [10, 15] . Oxidative stress has been postulated to be directly involved in the development of APAP-induced toxicity by the formation of the reactive metabolite NAPQI that is causing lipid peroxidation, depletion in antioxidants, mitochondrial dysfunction, and ultimately leading to DNA damage and necrotic cell death [7] . GSH significantly contributes to the detoxification of NAPQI as well as scavenging of peroxynitrite in APAP hepatotoxicity. Nevertheless, excessive NAPQI induces prominent depletion of GSH and subsequently results in lipid peroxidation, which is indicated by MDA accumulation [17] . In addition, the decline of GSH levels, APAP decreases the other antioxidants in the body, such as GPx, CAT, and SOD which act as a defense against oxidative stress status [18] . In agreement with previous research, the current study displayed an increase in MDA content with a depletion in hepatic antioxidants GSH, GPX, SOD, and CAT in APAP-treated rats. These findings align with prior reports, which reported that oxidative stress induced by APAP occurs due to utilizing antioxidants to neutralize NAPQI metabolites, which induces severe oxidative stress [19] [20] [21] . The current study revealed that DIA (25 and 50 mg/kg) treatment caused a distinct elevation of hepatic GSH, GPX, SOD, and CAT associated with marked depletion of MDA content in a dose-depended manner. These findings are compatible with several studies that reported that DIA neutralizes ROS and has a potent antioxidant capacity in different body tissues [10, 12, 15, 18, [22] [23] [24] . APAP-induced oxidative stress results in hepatocellular necrosis, which elicits immune cell infiltration and a cascade of inflammatory responses [7] . Damage-correlated molecular pattern molecules (DAMPS) such as HMGB1 are released by necrotic hepatocytes, activating pattern recognition receptors (PPRs) such as TLR4 and TLR9 [25] . The stimulation of TLRs signaling releases chemokines and other cytokines like IL-1 β, IL-6, and TNF-α, which attracts inflammatory cells via the family members of TLR as well as correlated pathways as the NF-κB pathway [26] . In APAP-induced hepatotoxicity, the activated TLR4 receptor provokes a series of active mediators that dissociate and translocate NF-κB to the nucleus, a fundamental nuclear transcription factor composed of p50, p52, p65, c-Rel, to commence inflammatory mediators' transcription [23, [27] [28] [29] . The knockout or blockade of TLR4 was reported to protect from inflammation in APAP hepatotoxicity. In the current work, HMGB1, TLR4, as well as NF-κB expression (p-65) were reduced in the hepatic tissue of DIA-treated rats in a dose-depended manner. These results proved that DIA ameliorates inflammation by inhibiting the HMGB1/TLR4 pathway after APAP acute-over dose administration in rats. This finding aligns with previous studies in different animal disease models [13, 30] .

In addition, TNF-α and IL-1β trigger immune cells and augment inflammatory response, which recruits monocytes and neutrophils in circulation to intensify inflammation and trigger a secondary inflammatory cascade. MPO activity is considered an early marker for inflammatory cell infiltration and predicts the incidence of inflammatory diseases [31] .In the same context, this study displayed a marked elevation in pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) levels and MPO levels in the APAP-treated rats [18] . These findings were reversed significantly and dose-dependently by DIA treatment which can be mediated via inhibition of NF-κB (p65). In context, several studies reported the anti-inflammatory effect of DIA in various animal models of inflammation-induced disease [12, [30] [31] [32] . In addition, Saleh et al., (1999) illustrated that DIA inhibited MPO levels in the mice model of carrageenan-induced pleurisy [33] . PPAR-γ contributes to several cellular events, glucose homeostasis, and adipogenesis. It significantly contributes to regulating inflammation as a suppressor of inflammation caused by oxidative stress. This role can be due to the direct inhibitory activity of transcription of pro-inflammatory genes as NF-κB, which is involved in inflammation [34, 35] . The therapeutic effect of PPAR-γ agonist has been determined in APAP-induced hepatotoxicity in rats [36] . Also, agonists of PPAR-γ were manifested as potent TLR4 inhibitors [9] . This study demonstrated that the hepatotoxic impacts of APAP induced a decline in the expression of PPAR-γ [36] . Conversely, DIA treatment showed elevation of PPAR-γ expression associated with the decline in NF-κB (p65) expression in a dose-related manner. These findings are consistent with Wen et al. 2019, who illustrated that Rhein, the active metabolite of diacerein, exerts its anti-inflammatory effect by upregulating the PPAR-γ and downregulating NF-κB expressions in the inflammatory cell model using LPS-stimulated RAW264.7 cell [37] .

In addition to oxidative stress, the contribution of apoptosis in the pathogenies of APAP-induced liver injury was confirmed [38] . Several studies emphasized that excessive ROS causes mitochondrial damage, which eventually activates the caspase cascade, leading to apoptosis. Caspase-3 has been proven to contribute to the pathway of hepatocellular apoptosis [33, 34, 39] . In addition, the balance between pro-apoptotic as well as anti-apoptotic Bcl-2 protein BAX displayed a pivotal role in regulating apoptosis during APAP hepatotoxicity [40] . Interestingly, promoting Bcl-2 protein expression can protect from APAP-induced apoptosis [41] . The present work demonstrated that acute dose of APAP caused a marked increase in the activity of caspase-3 as well as the expression of Bax with diminished expression of Bcl-2 [42] , that DIA therapy restored these results in a dose-related manner. The anti-apoptotic effect of DIA has been reported previously in different tissues [12, 22, 23, 30, 43, 44] .

The main limitations of our study were the failure to use immunoblotting analysis for NF-κB (p65) expression and apoptotic markers (procaspase-3 and cleaved caspase-3), along with TUNEL staining. Therefore, further investigation is suggested for these objectives.

DIA dose-dependently protects against liver damage induced by APAP via reducing oxidative stress, inflammatory process, as well as apoptosis. The anti-inflammatory activity attributed to the elevated expression of PPAR-γ, inducing suppression of HMGB-1/TLR4/NF-κB signaling pathway. Therefore, DIA represents an effective hepatoprotective therapy. Further research and clinical implications are needed.

Funding There was no particular grant for this study from any funding agency in the public, private, or not-for-profit sectors. 

Paracetamol (acetaminophen) poisoning

Drug-induced liver injury and COVID-19 infection: the rules remain the same

Acetaminophen-induced hepatotoxicity

Impact of liver functions by repurposed drugs for COVID-19 treatment

Acetaminophen hepatotoxicity: an updated review

Oxidative stress during acetaminophen hepatotoxicity: sources, pathophysiological role and therapeutic potential

Wogonin attenuates inflammation by activating PPAR-γ in alcoholic liver disease

Peroxisome proliferatoractivated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced Toll-like receptor 4 expression in vascular smooth muscle cells

Peroxisome proliferator activated receptor-γ modulates reactive oxygen species generation and activation of nuclear factor-κB and hypoxia-inducible factor 1α in allergic airway disease of mice

Diacerhein and rhein reduce the ICE-induced IL-1β and IL-18 activation in human osteoarthritic cartilage

Diacerein as a disease-modulating agent in osteoarthritis

Diacerein protects rats with liver ischemia/reperfusion damage: down-regulation of TLR4/ NFκ-B signaling pathway

Is montelukast as effective as N-acetylcysteine in hepatic injury due to acetaminophen intoxication in rats?

Diacerein protects against glycerol-induced acute kidney injury: modulating oxidative stress, inflammation, apoptosis and necroptosis

Theory and practice of histological techniques

Lactoferrin protects against acetaminophen-induced liver injury in mice

Hepatoprotective effect of essential phospholipids enriched with virgin coconut oil (Phoscoliv) on paracetamol-induced liver toxicity

Hepatoprotective effect of rhein against methotrexate-induced liver toxicity

Atorvastatin and diacerein reduce insulin resistance and increase disease tolerance in rats with sepsis

Molecular mechanisms underlying the effect of diacerein on trichloroacetic acid-induced hepatic pre-neoplastic lesions in rats

Protective effects of curcumin and silymarin against paracetamol induced hepatotoxicity in adult male albino rats

Hepatoprotective actions of ascorbic acid, alpha lipoic acid and silymarin or their combination against acetaminophen-induced hepatotoxicity in rats

Possible protective effect of diacerein on doxorubicin-induced nephrotoxicity in rats

Danger-associated molecular patterns (DAMPs): molecular triggers for sterile inflammation in the liver

Geniposide protected hepatocytes from acetaminophen hepatotoxicity by down-regulating CYP 2E1 expression and inhibiting TLR 4/NF-κB signaling pathway

Mechanism mediating the protective effect of diacerein in ischemia-reperfusion-induced testicular injury in rats

Diacerein ameliorates induced polycystic ovary in female rats via modulation of inflammasome/caspase1/IL1β and Bax/Bcl2 pathways. Naunyn Schmiedebergs Arch Pharmacol

Kaempferol from: penthorum chinense Pursh suppresses HMGB1/TLR4/NF-?B signaling and NLRP3 inflammasome activation in acetaminophen-induced hepatotoxicity

Diacerein: a potential multi-target therapeutic drug for COVID-19

Myeloperoxidase exacerbates secondary injury by generating highly reactive oxygen species and mediating neutrophil recruitment in experimental spinal cord injury

NF-κB pathway in autoinflammatory diseases: dysregulation of protein modifications by ubiquitin defines a new category of autoinflammatory diseases. Front Immunol

Effects of anti-inflammatory drugs upon nitrate and myeloperoxidase levels in the mouse pleurisy induced by carrageenan

PPAR-γ ligands modulate effects of LPS in stimulated rat synovial fibroblasts

Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components

Protective effect of pioglitazone, a PPARγ agonist against acetaminophen-induced hepatotoxicity in rats

Rhein attenuates lipopolysaccharide-primed inflammation through NF-κB inhibition in RAW264.7 cells: targeting the PPAR-γ signal pathway

CXC receptor-2 knockout genotype increases X-linked inhibitor of apoptosis protein and protects mice from acetaminophen hepatotoxicity

International Immunopharmacology Diacerein ameliorates testosterone-induced benign prostatic hyperplasia in rats: effect on oxidative stress, inflammation and apoptosis

Delayed-onset caspase-dependent massive hepatocyte apoptosis upon fas activation in bak/bax-deficient mice

Simultaneous detection of tumor cell apoptosis regulators Bcl-2 and Bax through a dual-signalmarked electrochemical immunosensor

Capsaicin alleviates acetaminophen-induced acute liver injury in mice

Saudi Journal of Biological Sciences Diacerein ameliorates kidney injury induced by cisplatin in rats by activation of Nrf2/Ho-1 pathway and Bax down-regulation

Diacerein downregulates NLRP3/caspase-1/IL-1β and IL-6/STAT3 pathways of inflammation and apoptosis in a rat model of cadmium testicular toxicity